Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed ovarian epithelial, fallopian tube, or extraovarian peritoneal cancer
• * Recurrent disease (any FIGO stage)
• * Not amenable to curative surgery or radiotherapy alone
• Failed prior primary platinum-based therapy at least 6 months after therapy discontinuation
• Measurable lesion by CT scan, MRI, chest x-ray, or sonography
• * Physical examination allowed for documenting lymph node and skin metastases
• * Physical gynecological examination allowed for well-defined palpable tumor lesions
• * Increase in CA 125 without any measurable tumor is not acceptable as indication of recurrence
• No CNS metastases
• No tumor of borderline malignancy
• PATIENT CHARACTERISTICS:
• Age
• 18 to 65
• Performance status
• ECOG 0-2
• Life expectancy
• At least 24 weeks
• Hematopoietic
• Neutrophil count at least 1,500/mm3
• Platelet count at least 100,000/mm3
• Hepatic
• Not specified
• Renal
• Creatinine clearance at least 60 mL/min
• No chronic or acute renal failure
• Cardiovascular
• Cardiovascular function sufficient for hyperthermia treatment by stress-ECG
• No cardiomyopathy with impaired ventricular function
• No New York Heart Association class III or IV heart disease
• No cardiac arrhythmias influencing LVEF and requiring medication
• No myocardial infarction or angina pectoris within the past 6 months
• No uncontrolled arterial hypertension
• Pulmonary
• Pulmonary function sufficient for hyperthermia treatment by pulmonary function tests
• Other
• No untreated endocrinological disease (e.g., hyperthyroidism or diabetes mellitus)
• No other primary malignancy except carcinoma in situ of the cervix or adequately treated basal cell skin cancer
• No contraindication against hyperthermia treatment (e.g., photodermatosis, history of malignant hyperthermia, or claustrophobia)
• No hypersensitivity to carboplatin, ifosfamide, or any other study medication
• Not pregnant or nursing
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Not specified
• Chemotherapy
• See Disease Characteristics
• No concurrent cytotoxic or other antineoplastic therapy
• Endocrine therapy
• Concurrent hormone replacement therapy allowed
• Concurrent steroid antiemetics allowed
• Radiotherapy
• See Disease Characteristics
• At least 1 year since prior radiotherapy (tumoricidal dose) of the pelvis
• Concurrent palliative local radiotherapy for painful (nonprogressive) existing lesion is allowed if other measurable sites are present
• No concurrent radiotherapy to a second existing lesion
• Surgery
• See Disease Characteristics
• Other
• No prior form of hyperthermic therapy
• At least 3 weeks since other medications as part of another clinical study
• At least 3 weeks since prior investigational agents
• At least 6 weeks since prior betablockers
• No concurrent photosensitizing drugs
• No concurrent betablockers
• No other concurrent anticancer therapy